

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
05 December 2024 (05.12.2024)



(10) International Publication Number
WO 2024/245953 A1

(51) International Patent Classification:

A61K 9/20 (2006.01) A61K 47/38 (2006.01)

A61K 47/02 (2006.01)

(21) International Application Number:

PCT/EP2024/064426

(22) International Filing Date:

24 May 2024 (24.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23175788.1 26 May 2023 (26.05.2023) EP

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151-85
Södertälje (SE).

(72) Inventors: **AL HUSBAN, Farhan Abdel Karim Mo-**
hammad; AstraZeneca UK Limited, 1 Francis Crick Ave-
nue, Cambridge Biomedical Campus, Cambridge Cam-
bridgeshire CB2 0AA (GB). **MORGAN, Tomos Rees**; As-
traZeneca UK Limited, 1 Francis Crick Avenue, Cambridge
Biomedical Campus, Cambridge Cambridgeshire CB2 0AA
(GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-**
TY; Eastbrook House, Shaftesbury Road, Cambridge Cam-
bridgeshire CB2 8BF 6GH (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: PHARMACEUTICAL COMPOSITIONS



Compound [I]

(57) Abstract: The present specification relates to pharmaceutical compositions comprising Compound [I] ((S)-4- amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide), microcrystalline cellulose (MCC) and dicalcium phosphate anhydrous (DCPA), for example tablets with immediate release properties.

WO 2024/245953 A1